Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

-Evaluate the efficacy and safety of Shenyankangfu Tablets to control the proteinuria of patients with primary glomerulonephritis compare with Losartan potassium.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese PLA General Hospital
• Collaborator: Tianjin TongRenTang Group Co., Ltd.
• Treatments: Losartan

Criteria

Inclusion

• Diagnosed with primary glomerulonephritis

• Aged from 18 to 70 years，male or female

• Blood pressure can be controlled ≤140/90mmHg

• GFR≥45ml/min/1.73㎡

• 0.5g≤24 hours proteinuria≤3.0g

• Traditional Chinese medicine syndrome conform Qi-Yin Deficiency

• Obtain the agreement of patients or their guardians, and signed informed consent file

Exclusion Criteria:

• secondary nephropathy

• Take the glucocorticoid,immunosuppressants and Tripterygium drug in the last 12 months

• Take other Chinese patent medicine and decoction which can reduce proteinuria in the last 2 weeks

• Take renin-angiotensin system blockers in last 4 weeks

• Combined with severe primary disease of heart, brain, liver and hematopoietic system, or other serious diseases can affect patient's life

• Pregnant or lactating women

• Allergic predisposition or known to be allergic to the drug composition

• Blood presser <90/60mmHg

• With unilateral or bilateral renal artery stenosis

• With mental disorders and poor compliance

• Be suspected or confirmed with alcohol, drug abuse history

• Be participating in another clinical study at the same period